Pharmacoinvasive strategy versus primary coronary intervention on myocardial tissue-level reperfusion in ST-elevation myocardial infarction: insight from the pilot study of early myotrail
Background Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for ST-elevation myocardial infarction (STEMI), but most patients do not arrive at a PCI facility within the recommended 90-minute of first medical contact (FMC).In Chinese context pharmacoinvasive therapy might be a more practical solution.To provide more definitive evidence for the efficacy and safety of pharmacoinvasive strategy, we designed the Early MYO(Early Routine Catheterisation or Rescue Coronary Intervention after rt-PA vs.PPCI in STEMI) Trial, an open-label,prospective, non-inferiority, multicentre randomized study of STEMI patients to compare pharmacoinvasive strategy with PPCI on myocardial tissue-level reperfusion in STEMI.We present pilot study results in 87 consecutive STEMI patients recruited at the Renji Hospital for the Early MYO Trial.
PU Jun HE Ben GE Heng ZHANG Tuo L(U) Ting ZHOU Wen SONG Wei DU Yong-ping JIN Shu-xuan WANG Wei
Department of Cardiology,Shanghai Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China
国内会议
北京
英文
211-211
2013-03-20（万方平台首次上网日期，不代表论文的发表时间）